{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:27:21Z","timestamp":1790332041019,"version":"4.1.0"},"reference-count":90,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The 1,3-benzothiazole (BTZ) ring may offer a valid option for scaffold-hopping from indole derivatives. Several BTZs have clinically relevant roles, mainly as CNS medicines and diagnostic agents, with riluzole being one of the most famous examples. Riluzole is currently the only approved drug to treat amyotrophic lateral sclerosis (ALS) but its efficacy is marginal. Several clinical studies have demonstrated only limited improvements in survival, without benefits to motor function in patients with ALS. Despite significant clinical trial efforts to understand the genetic, epigenetic, and molecular pathways linked to ALS pathophysiology, therapeutic translation has remained disappointingly slow, probably due to the complexity and the heterogeneity of this disease. Many other drugs to tackle ALS have been tested for 20 years without any success. Dexpramipexole is a BTZ structural analog of riluzole and was a great hope for the treatment of ALS. In this review, as an interesting case study in the development of a new medicine to treat ALS, we present the strategy of the development of dexpramipexole, which was one of the most promising drugs against ALS.<\/jats:p>","DOI":"10.3390\/molecules25153320","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T11:26:01Z","timestamp":1595503561000},"page":"3320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies"],"prefix":"10.3390","volume":"25","author":[{"given":"Serge","family":"Mignani","sequence":"first","affiliation":[{"name":"Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologique, Universit\u00e9 Paris Descartes, PRES Sorbonne Paris Cit\u00e9, CNRS UMR 860, 45, rue des Saints Peres, 75006 Paris, France"},{"name":"CQM-Centro de Qu\u00edmica da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9020-105 Funchal, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Majoral","sequence":"additional","affiliation":[{"name":"Laboratoire de Chimie de Coordination du CNRS, 205 route de Narbonne, 31077 Toulouse CEDEX 4, France"},{"name":"Universit\u00e9 Toulouse, 118 route de Narbonne, 31077 Toulouse CEDEX 4, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8816-9369","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Desaphy","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche e Oncologia Umana, Scuola di Medicina, Universit\u00e0 degli Studi di Bari Aldo Moro, Piazza Giulio Cesare, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7079-5994","authenticated-orcid":false,"given":"Giovanni","family":"Lentini","sequence":"additional","affiliation":[{"name":"Dipartimento di Farmacia\u2014Scienze del Farmaco, Universit\u00e0 degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ejmech.2019.07.019","article-title":"An insight into the medicinal perspective of synthetic analogs of indole: A review","volume":"180","author":"Garg","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"103021","DOI":"10.1016\/j.bioorg.2019.103021","article-title":"Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives","volume":"89","author":"Kumari","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cjoc.201900446","article-title":"Recent advances in the catalytic functionalization of \u201celectrophilic\u201d indoles","volume":"38","author":"Cerveri","year":"2020","journal-title":"Chin. J. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1124\/dmd.115.064246","article-title":"Indole and Tryptophan Metabolism: Endogenous and Dietary Routes to Ah Receptor Activation","volume":"43","author":"Troy","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e11621","DOI":"10.15252\/emmm.201911621","article-title":"Targeting the pregnane X receptor using microbial metabolite mimicry","volume":"12","author":"Kopp","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1039\/C9MD00396G","article-title":"Scaffold-hopping as a strategy to address metabolic liabilities of aromatic compounds","volume":"11","author":"Lazzara","year":"2020","journal-title":"RSC Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1021\/jm200187y","article-title":"The medicinal chemist\u2019s toolbox: An analysis of reactions used in the pursuit of drug candidates","volume":"54","author":"Roughley","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1070\/RC2012v081n02ABEH004222","article-title":"Fragment-based lead design","volume":"81","author":"Filz","year":"2012","journal-title":"Russian Chem. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2014.12.031","article-title":"Thiazole: A promising heterocycle for the development of potent CNS active agents","volume":"92","author":"Mishra","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_12","first-page":"104","article-title":"enzothiazole\u2014Versatile heterocyclic nucleus in medicinal chemistry: A review","volume":"5","author":"Karumudi","year":"2015","journal-title":"B. Int. J. Pharm. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/jm701122q","article-title":"Generation of a set of simple, interpretable ADMET rules of thumb","volume":"51","author":"Gleeson","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e00160","DOI":"10.1002\/prp2.160","article-title":"Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine","volume":"3","author":"Gualdani","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejmech.2003.11.014","article-title":"Synthesis and structure-activity relationships of new antimicrobial active multisubstituted benzazole derivatives","volume":"39","author":"Yalcin","year":"2004","journal-title":"Eur. J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.30750\/ijpbr.2.3.14","article-title":"Synthesis, characterization and evaluation of anti-inflammatory and analgesic activity of benzothiazole derivatives","volume":"2","author":"Verma","year":"2014","journal-title":"Indian J. Pharm. Biol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00775-007-0232-z","article-title":"Benzothiazole bipyridine complexes of ruthenium(II) with cytotoxic activity","volume":"12","author":"Spillane","year":"2007","journal-title":"J. Biol. Inorg. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.expneurol.2014.02.023","article-title":"Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs","volume":"255","author":"Desaphy","year":"2014","journal-title":"Exp. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejmech.2009.09.037","article-title":"Synthesis, Anticonvulsant Activity and 3D-QSAR Study of Some prop-2-eneamido and 1-acetyl-pyrazolin Derivatives of Aminobenzothiazole","volume":"45","author":"Amnerkar","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/sj.cdd.4402159","article-title":"Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-kappaB transcriptional activity","volume":"14","author":"Plesnila","year":"2007","journal-title":"Cell. Death Differ."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/182421a0","article-title":"Chemical aspects of selective toxicity","volume":"182","author":"Albert","year":"1958","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.drudis.2016.01.005","article-title":"Compound high-quality criteria: A new vision to guide the development of drugs, current situation","volume":"21","author":"Mignani","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/17460441.2017.1365056","article-title":"Ligand efficiency metrics in drug discovery: The pros and cons from a practical perspective","volume":"12","author":"Cavalluzzi","year":"2017","journal-title":"Exp. Opin. Drug Discv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular Properties That Influence the Oral Bioavailability of Drug Candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/cc9800071","article-title":"Knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases","volume":"1","author":"Ghose","year":"1999","journal-title":"J. Comb. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1008130001697","article-title":"Property distribution of drug-related chemical databases","volume":"14","author":"Oprea","year":"2000","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1359-6446(03)02831-9","article-title":"A \u201crule of three\u201d for fragment-based lead discovery?","volume":"8","author":"Congreve","year":"2003","journal-title":"Drug Discov. Today"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from flatland: Increasing saturation as an approach to improving clinical success","volume":"52","author":"Lovering","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: Misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8238","DOI":"10.1021\/jm5007935","article-title":"Rational Use of Plasma Protein and Tissue Binding Data in Drug Design","volume":"57","author":"Liu","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1517\/17460441.2.1.51","article-title":"The importance of plasma protein binding in drug discovery","volume":"2","author":"Trainor","year":"2007","journal-title":"Exp. Opin. Drug Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/tx200211v","article-title":"Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety","volume":"24","author":"Meanwell","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1080\/17460441.2017.1380623","article-title":"Novel CNS drug discovery and development approach: Model-based integration to predict neuro-pharmacokinetics and pharmacodynamics","volume":"12","author":"Yamamoto","year":"2017","journal-title":"Exp. Opin. Drug Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/aps.2009.24","article-title":"Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases","volume":"30","author":"Dong","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1385\/MN:29:1:15","article-title":"Pathogenesis of Parkinson\u2019s disease: Prospects of neuroprotective and restorative therapies","volume":"29","year":"2004","journal-title":"Mol. Neurobiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00004850-200403000-00001","article-title":"Huntington\u2019s disease: Present treatments and future therapeutic modalities","volume":"19","author":"Bonelli","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1179\/016164107X159225","article-title":"Do sodium channel blockers have neuroprotective effect after onset of ischemic insult?","volume":"29","author":"Ates","year":"2007","journal-title":"Neurol. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"Controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole study group","volume":"330","author":"Bensimon","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00003495-199652040-00010","article-title":"Riluzole: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis","volume":"52","author":"Bryson","year":"1996","journal-title":"Drug Eval."},{"key":"ref_41","first-page":"CD001447","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"2","author":"Miller","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_42","first-page":"61","article-title":"Riluzole: Real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis","volume":"7","author":"Hinchcliffe","year":"2017","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(18)30091-7","article-title":"Riluzole, disease stage and survival in ALS","volume":"17","author":"Dharmadasa","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_44","unstructured":"Enzmann, H. (2019, May 24). Withdrawal of Radicava, (Edaravone), 30 mg Solution for Infusion-EMEA\/H\/C\/004938\/0000. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/withdrawal-letter\/withdrawal-letter-radicava_en.pdf."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1038\/s41598-019-39676-3","article-title":"Elucidating the contribution of skeletal muscle ion channels to amyotrophic lateral sclerosis in search of new therapeutic options","volume":"9","author":"Camerino","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.2174\/0929867321666140601162710","article-title":"Potential therapeutic drugs and methods for the treatment of amyotropic lateral sclerosis","volume":"21","author":"Yacilla","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1212\/WNL.47.6_Suppl_4.233S","article-title":"The pharmacology and mechanism of action of riluzole","volume":"47","author":"Doble","year":"1996","journal-title":"Neurology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0014-2999(93)90037-I","article-title":"The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1","volume":"250","author":"Martin","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/B:CEMN.0000012717.37839.07","article-title":"Riluzole enhances glutamate uptake in rat astrocyte cultures","volume":"24","author":"Frizzo","year":"2004","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/jnc.13606","article-title":"In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3","volume":"138","author":"Schmidt","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"438","DOI":"10.9758\/cpn.2019.17.3.438","article-title":"Riluzole Selective Antioxidant Effects in Cell Models Expressing Amyotrophic Lateral Sclerosis Endophenotypes","volume":"17","author":"Sala","year":"2019","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1734-1140(10)70323-6","article-title":"Intracerebroventricular administration of riluzole prevents morphine-induced apoptosis in the lumbar region of the rat spinal cord","volume":"62","author":"Hassanzadeh","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1055\/s-0038-1676654","article-title":"The effects of riluzole on cisplatin-induced ototoxicity","volume":"23","author":"Uygur","year":"2019","journal-title":"Int. Arch. Otorhinolaryngol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/WCO.0000000000000730","article-title":"Epidemiology of amyotrophic lateral sclerosis: Anupdate of recent literature","volume":"32","author":"Longinetti","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1021\/jm980202u","article-title":"Riluzole series. Synthesis and in vivo \u201cantiglutamate\u201d activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines","volume":"42","author":"Jimonet","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1021\/acsmedchemlett.8b00103","article-title":"Riluzole\u2212triazole hybrids as novel chemical probes for neuroprotection in amyotrophic lateral sclerosis","volume":"9","author":"Sweeney","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pharmthera.2013.08.003","article-title":"The role of heat shock proteins in amyotrophic lateral sclerosis: The therapeutic potential of arimoclomol","volume":"141","author":"Kalmar","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"28649","DOI":"10.1038\/srep28649","article-title":"The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice","volume":"6","author":"Akamatsu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","article-title":"Efficacy and safety of ceftriaxone for amyotrophic lateral sclerosis: Results of a multi-stage, randomised, double-blind, placebo-controlled, phase 3 study","volume":"13","author":"Cudkowicz","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Nagata, E., Ogino, M., Iwamoto, K., Kitagawa, Y., Iwasaki, Y., Yoshii, F., and Ikeda, J.E. (2016). Bromocriptine mesylate attenuates amyotrophic lateral sclerosis: A phase 2a, randomized, double-blind, placebo-controlled research in Japanese patients. PloS ONE, 24.","DOI":"10.1371\/journal.pone.0152845"},{"key":"ref_61","unstructured":"Pasinetti, G. (2006). Treatment of Amyotrophic Lateral Sclerosis with Nimesulide. (20060041022A1), U.S. Patent."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/13543784.2019.1627324","article-title":"Stem cell treatments for amyotrophic lateral sclerosis: A critical overview of early phase trials","volume":"28","author":"Goutman","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_63","unstructured":"(2020, July 22). ALS. Available online: https:\/\/www.sciencedaily.com\/releases\/2018\/05\/180521131659.htm."},{"key":"ref_64","first-page":"486","article-title":"Pharmacological properties of benzazoles. I. Relationship between structure and paralyzing action","volume":"105","author":"Domino","year":"1952","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_65","first-page":"2843","article-title":"Quantitative structure activity relationship of riluzole series as anticonvulsants","volume":"19","author":"Gunakkunru","year":"2007","journal-title":"Asian J. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1021\/jm020044d","article-title":"Novel p53 inactivators with neuroprotective action: Syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-Imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives","volume":"45","author":"Zhu","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1755-5949.2008.00048.x","article-title":"KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine dihydrocholride monohydrate] for the treatment of amyatropic lateral sclerosis","volume":"14","author":"Gribkoff","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ferrari-Toninelli, G., Maccarinelli, G., Uberti, D., Buerger, E., and Memo, M. (2010). Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole. BMC Pharmacol., 10.","DOI":"10.1186\/1471-2210-10-2"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2165\/11585090-000000000-00000","article-title":"Role of pramipexole in the management of Parkinson\u2019s disease","volume":"24","author":"Antonini","year":"2010","journal-title":"CNS Drugs"},{"key":"ref_70","first-page":"230","article-title":"Effects of Benzothiazolamines on voltage-gated sodium channels","volume":"246","author":"Farinato","year":"2018","journal-title":"Handb. Exp. Pharmacol"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/j.pain.0000000000001774","article-title":"Dexpramipexole blocks Nav1.8 sodium channels and provides analgesia in multiple nociceptive and neuropathic pain models","volume":"161","author":"Urru","year":"2020","journal-title":"Pain"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Vieira, F.G., LaDow, E., Moreno, A., Kidd, J.D., Thompson, K., Gill, A., Finkbeiner, S., and Perrin, S. (2014). Dexpramipexole is ineffective in two models of ALS related neurodegeneration. PLOS ONE, 19.","DOI":"10.1371\/journal.pone.0091608"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jddst.2017.11.026","article-title":"Preparation, statistical optimization and in vitro evaluation of pramipexole prolonged delivery system based on (3-hydroxybutyrate-co-3-hydroxyvalerate nanoparticles","volume":"44","author":"Javan","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/mds.22254","article-title":"Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice","volume":"23","author":"Trenkwalder","year":"2008","journal-title":"MoV. Disord."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neulet.2018.09.064","article-title":"Repurposing of dexpramipexole to treatment of neonatal hypoxic\/ischemic encephalopathy","volume":"687","author":"Muzzia","year":"2018","journal-title":"Neurosci. Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1007\/s00018-013-1415-0","article-title":"Therapeutic neuroprotective agents for amyotrophic lateral sclerosis","volume":"70","author":"Pandya","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_77","unstructured":"Juarez, J.M., and Silva Guisasola, G.O. (2006). Method for the Resolution of 2-amino-6-propilamino-4,5,6,7 Tetrahydrobenzothiazol and Intermediate Compounds. (Application No. 2006120268A1), WO Patent."},{"key":"ref_78","unstructured":"Siesel, D.A., Ramirez, C., and Meckler, H. (2006). Process for Preparing Chirality Pure 2-amino-6-(alkyl)amino-4,5,6,7-tetrahydrobenzothiazoles by Liquid Chromatographic Resolution. (Application No. 200612276A1), WO Patent."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1021\/op1000989","article-title":"A novel scalable synthesis of pramipexole","volume":"14","author":"Zivec","year":"2010","journal-title":"Org. Process. Res. Dev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1021\/jm00386a009","article-title":"Dopamine autoreceptor agonists: Resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analogue of apomorphine","volume":"30","author":"Schneider","year":"1987","journal-title":"J. Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.tetasy.2014.07.011","article-title":"Baker\u2019s yeast catalyzed preparation of a new enathiomerically pure synthon of (S)-pramipexole and its enatiomer (dexpramipexole)","volume":"25","author":"Ferraboschi","year":"2014","journal-title":"Tetrahedron Asymmetry"},{"key":"ref_82","unstructured":"(2017, September 06). News and Events-KNOPP Bioscience. Available online: https:\/\/knoppbio.com\/index.php?section=news&subsection=news&id=56."},{"key":"ref_83","first-page":"50","article-title":"R(+)pramipexole as a mitochondrally focused neuroprotectant: Initial early phase studies in ALS","volume":"9","author":"Wang","year":"2008","journal-title":"ALS"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/nm.2579","article-title":"The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis","volume":"17","author":"Cudkowicz","year":"2011","journal-title":"Nat. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2018-02-835330","article-title":"Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes","volume":"132","author":"Panch","year":"2018","journal-title":"Blood"},{"key":"ref_86","unstructured":"(2020, July 22). Pharmaceutical Daily-Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma. Available online: http:\/\/www.pharmaceuticaldaily.com\/knopp-biosciences-enters-collaboration-with-leading-uk-investigators-to-commence-phase-2-clinical-trial-of-dexpramipexole-in-severe-eosinophilic-asthma."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"16785","DOI":"10.1039\/C9NJ02966D","article-title":"Design, complexing and catalytic properties of phosphorus thiazoles and benzothiazoles: A concise overview","volume":"43","author":"Majoral","year":"2019","journal-title":"New J. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ccr.2017.12.004","article-title":"Interactions gold\/phosphorus dendrimers.Versatile ways to hybrid organic-metallic macromolecules","volume":"358","author":"Majoral","year":"2018","journal-title":"Coord. Chem. Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00401-018-1835-x","article-title":"Energy metabolism in ALS: An underappreciated opportunity?","volume":"135","author":"Vandoorme","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"107440","DOI":"10.1016\/j.jmgm.2019.107440","article-title":"Amino-carboxamide benzothiazoles as potential LSD1 hit inhibitors. Part I: Computational fragment-based drug design","volume":"93","author":"Alnabulsi","year":"2019","journal-title":"J. Mol. Graph. Model."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/15\/3320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:50:47Z","timestamp":1760176247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/15\/3320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":90,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["molecules25153320"],"URL":"https:\/\/doi.org\/10.3390\/molecules25153320","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]}}}